NA
TLX

NewEdge Advisors’s Telix Pharmaceuticals TLX Stock Holding History

NewEdge Advisors’s Portfolio TLX Stock Details TLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$18.4K Hold
1,920
– – ﹤0.01% 3219
2025
Q4 		$14.4K Sell
1,920
-480
-20% -$4.62K ﹤0.01% 3356
2025
Q3 		$23K Buy
+2,400
New +$29.4K ﹤0.01% 3081

Other funds holding TLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return
PIC
Portland Investment Counsel Burlington, Ontario, Canada $312M AUM 53.32% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
IWC
Integrated Wealth Concepts Waltham, Massachusetts $12.5B AUM 18.49% 1-Year Est. Return
RBI
Raiffeisen Bank International Vienna, Austria $8.53B AUM 46.94% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Mariner
Mariner Overland Park, Kansas $85.7B AUM 24.21% 1-Year Est. Return

NewEdge Advisors's TLX Position: Q1 2026 in Review

NewEdge Advisors held its Telix Pharmaceuticals (TLX) position steady in Q1 2026 at 1,920 shares worth $18.4K. The position accounts for ﹤0.01% of the portfolio, ranked #3219.

NewEdge Advisors first reported a position in TLX in Q3 2025 and has held it in 3 quarters since. The position peaked at $23K in Q3 2025. 39 funds tracked by Wall St. Rank hold TLX as of Q1 2026.

  • NewEdge Advisors held 1,920 shares of Telix Pharmaceuticals worth $18.4K as of Q1 2026.
  • NewEdge Advisors left its Telix Pharmaceuticals share count unchanged in Q1 2026.
  • Telix Pharmaceuticals made up ﹤0.01% of NewEdge Advisors's portfolio in Q1 2026, its #3219 holding.
  • NewEdge Advisors first reported a position in Telix Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • NewEdge Advisors's Telix Pharmaceuticals position peaked at $23K in Q3 2025.
  • 39 funds tracked by Wall St. Rank held Telix Pharmaceuticals as of Q1 2026.

Based on NewEdge Advisors's 13F filing for Q1 2026, filed 18 May 2026.